Keren Leshem has been CEO of ViSci Ltd. since 2011, where she has successfully led all research and development involving the Company’s sustained drug delivery platform. She advanced the Eye-D™ program from early stage research to Phase 1/2a clinical development. Her expertise lies in the field of Glaucoma and in ophthalmic pharmaceutical and medtech innovation. Before ViSci Ltd., Keren headed AOPharma Ltd., where she was responsible for development of novel ocular drug delivery solutions. In addition, Keren was an executive consultant to several start-up companies in the biotech and medtech fields. There she was not only consulting on CMC, preclinical & clinical development, but successfully used her 15 years of experience in international business development and fund raising. Keren completed her undergraduate education in Business from New England University and has a marketing MBA from Clark University in MA.